A substantial body of literature highlights the challenges that exist providing palliative and end-of-life care for people with a hematological malignancy. This group of patients commonly: 1) receive aggressive care close to the end of life (such as chemotherapy administration, emergency admissions, intensive care unit admissions), 2) die in hospital; and 3) have palliative care integrated later and less often compared to their solid tumor counterparts. Amongst other issues, a significant problem is reported to be difficulties in accurately predicting mortality at the end of life for these patients due to a fluctuating and unpredictable illness trajectory. There can often be potential for cure in the face of critical illness or advanced disease. People with a hematological malignancy who are nearing the end of their life can experience a swift change in the goals of care from curative or life-prolonging, to palliative.